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Abstract
Data are sparse on Mycobacterium tuberculosis infection among patients with cancer in Egypt. We sought to detect the presence of
tuberculosis (TB) disease among patients with malignant conditions and suspected TB and to study the main risk factors. Also, we com-
pared different diagnostic procedures and detected the antimicrobial susceptibility of M. tuberculosis isolates against rifampin and isonia-
zid. One hundred patients were included in this study, all of them had malignant conditions and were suspected by the clinicians of
having TB. Identiﬁcation of M. tuberculosis in different specimens was performed by smear microscopy, followed by Lowenstein–Jensen
medium and Mycobacterium growth indicator tube (MGIT) cultures and artus real-time PCR. In addition, an indirect MGIT anti-TB sus-
ceptibility test was carried out against rifampin and isoniazid. A total of 76% of studied cases were found to be TB positive. The fre-
quencies of TB-positive cases in the bronchogenic, haematological and solid tumour malignancy groups were 21%, 25% and 30%,
respectively. Signiﬁcant differences between pulmonary and extrapulmonary TB in different malignancy groups were recorded. Real-time
PCR showed the highest overall diagnostic efﬁciency. Multidrug-resistance of M. tuberculosis to both rifampin and isoniazid was detected
in 28.6% of examined isolates. Infection in cancer patients with TB was signiﬁcantly more often recorded among elderly patients and
those suffering from poverty. Pulmonary TB is more common than extrapulmonary TB in patients with malignancy. Real-time PCR is
the most accurate and rapid method for TB diagnosis. MGIT-rifampin resistance may be used as a reliable marker for detection of multi-
drug-resistant TB. Diagnosis and instituting treatment course for active or latent TB infection are crucial before starting anticancer therapy.
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Introduction
Although Egypt is not one of the 22 countries listed by
WHO for their high levels of tuberculosis (TB) infection, TB
is a considerable public health problem in Egypt [1]. The
inﬂammation and ﬁbrosis associated with TB could promote
malignancy. This was mainly attributed to blocking of lym-
phatics by pulmonary scarring and ﬁbrosis causing a delay in
clearance of activated leucocytes and consequently an
enhancement of metastatic cell deposition within ﬁbrotic
areas [2–4].
On the other hand, malnutrition and immunosuppression
caused by cancer were reported as possible primary causes
of contraction or reactivation of TB infection. Recently, Wu
et al. [5] have described cancers as risk factors for TB.
Although a causal mechanism is not proven, lung cancer risk,
especially adenocarcinoma, was reported to be increased
with TB especially if associated with chronic obstructive pul-
monary disease or smoking-related cancers [4]. The possibil-
ity of co-infection with TB was reported in patients with a
malignancy, especially those with lung cancer [6].
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Finally, clinicians should be aware of the similarities
between TB and cancer, especially lung cancer [7–9]. Some
patients with chronic and slowly progressive pulmonary TB
were mistakenly thought to have lung cancer, such as bronc-
hoalveolar carcinoma or pulmonary non-Hodgkin’s lym-
phoma [10,11]. Due to the similarity between some clinical
and radiographic aspects of TB with various diseases, extra-
pulmonary TB may be misdiagnosed as cancer.
Documentation of resistance among TB bacilli is globally
escalating [12,13]. However, there is a shortage of reports
concerning antimycobacterial resistance and prevalence of
M. tuberculosis isolates from cancer patients in hospitals in
Egypt. Consequently, this work aimed to measure the rela-
tive frequency of TB disease in patients with malignant condi-
tions and to study other TB risk factors in Egypt during the
period 2007–2010. Moreover, the study aimed to compare
different diagnostic procedures as well as to detect the anti-
microbial susceptibility patterns of M. tuberculosis isolates
against rifampin and isoniazid.
Patients and Methods
Patients’ specimens
Sputum, pus, ascetic ﬂuids and bronchoalveolar lavage were
collected as per the clinician’s recommendations from 100
patients with cancer who were suspected of having TB by
the clinicians at the National Cancer Institute of Egypt during
the period 2007–2010. Patients ﬁlled in and signed a ques-
tionnaire that included demographic data, past medical his-
tory and agreement of inclusion in the study.
Microbial identiﬁcation
Mycobacterium tuberculosis strains were identiﬁed using micro-
scopic examination of smears stained by the Ziehl–Neelsen
technique. Decontaminated samples were inoculated into
Lowenstein Jensen Medium (LJ) (Becton Dickinson, Diagnostic
Instrument Systems, Inc., Franklin Lakes, NJ, USA) as well as
Mycobacterium growth indicator tube (MGIT) (BBL, Becton
Dickinson, Diagnostic Instrument Systems, Inc., Franklin Lakes,
NJ, USA) for the purpose of conﬁrmation and comparison of
their efﬁcacy [14].
Real-time PCR
DNA extraction was performed on the decontaminated sam-
ples using a QIAamp DNA minikit (Qiagen Co., Valencia,
CA, USA). It was designed to amplify the region encoding
the gene for 16S rRNA within the Mycobacterium genome
and to detect all M. tuberculosis complex organisms, including
M. tuberculosis, M. africanum, M. bovis and M. microti. The spe-
ciﬁc amplicons (a 159 bp region of the mycobacterial gen-
ome) were detected directly using the 5¢-nuclease (TaqMan)
probe labelled with FAM dye [15] and JOE dye for detection
of Internal Control (M. tuberculosis IC). Ampliﬁcation was
carried out using an artus M. tuberculosis PCR Kit (Qia-
gen) on Step One Applied Biosystems thermal cycle, and
manufacturers’ protocols were followed [16].
Results revealed positive detection of M. tuberculosis whether
solid cultures, liquid cultures or real-time PCR were compared.
Indirect anti-TB MGIT susceptibility test
Due to the low bacillary load in specimens, as indicated by
Ziehl–Neelsen (ZN) smears, indirect anti-TB MGIT suscepti-
bility test (indirect AST) was performed to detect the iso-
lates’ resistance pattern.
Isoniazid (1 mg/mL) stock aqueous solution and rifampin
(250 mg/mL) stock solution in dimethylsulphoxide : water
(1:1) mixture were prepared. Tubes containing rifampin or
isoniazid at concentrations of 1.0 and 0.1 mg/mL, respec-
tively, and one growth control (GC) tube were prepared for
each inoculum [17,18].
All MGIT tubes were incubated at 37C and were
checked daily for growth indication from the third to the
twelfth day via 365-nm UV trans-illuminator. Each isolate
was considered susceptible if the drug-containing tube did
not ﬂuoresce within 2 days of positivity in the GC tube. A
resistant strain was considered if the drug-containing tube
showed growth on the day of GC positivity or within 2 days.
Statistical analysis
Categorical data were summarized as a percentage. Compar-
isons among different groups were performed using GRAPH
PAD INSTAT by chi-square and two-sided p-value and p <0.05
was considered signiﬁcant.
Results
Frequency of TB in clinical specimens isolated from sus-
pected patients
The frequencies of TB-positive cases in bronchogenic, haema-
tological and solid tumour malignancy groups were 21%, 25%
and 30%, respectively. Positive TB was detected in 76 of the
100 cancer patients. During the 3 years of the study, TB-posi-
tive cases represented 65.9%, 86.4% and 78.9%, respectively.
There was a signiﬁcant difference (p <0.05) between pulmo-
nary TB (PTB) and extrapulmonary TB (ETB), (Table 1).
Mean age of TB-positive patients with malignancy was
47 ± 17.6 years (mean ± SD). Although, 24 (31.5%) TB-posi-
tive patients with malignancy were older than 55 years, there
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was a signiﬁcant increase (p <0.05) in contraction of TB
infection among elderly patients. Concerning gender, there
was not a signiﬁcant difference between male and female TB-
positive patients.
Poverty was found as a risk factor for all TB-positive
cases, where patients are on a low or ﬁxed income, live in
remote areas, these factors can lead to difﬁcult access to the
medical care needed to diagnose and treat TB. There is
coexistence between TB infection and malignancies in all
cases. Other studied risk factors include a number of dis-
eases such as hepatosplenic disorders (i.e. splenectomy, liver
cirrhosis, hepatitis C virus, hepato-splenomegaly), anaemia,
diabetes mellitus and hypertension; these were recorded in
frequencies of 6.6%, 6.6%, 3.9% and 3.9% of TB-positive
cases, respectively.
Our study reported smoking in 3.9% of TB-positive
patients. Past TB history was recorded in 5.2% of TB-positive
cases. However, there was no signiﬁcant correlation statisti-
cally (p >0.05) between the presence of primary or recur-
rent TB infection and TB history. Additionally, there was no
signiﬁcant difference (p >0.05) between the diagnosis of PTB
and ETB cases with regards to patient age, gender and
demographic characteristics (Table 2).
In the current study, the proportion of males to females
regarding the sputum ZN smear was statistically signiﬁcant
(p <0.05), where ZN-smear-positive female and male sputa
were 70.9% and 92.5%, respectively of total TB-positive spu-
tum (Table 3). However, no statistically signiﬁcant difference
was detected between different age groups regarding the
sputum ZN smear positivity, a signiﬁcant difference (p <0.05)
was only recorded for the older age group >65 years. The
present study was based on testing the following specimens:
sputum, pus, ascetic ﬂuid and bronchoalveolar lavage, their
TB diagnostic efﬁciencies were 75.8%, 76.6%, 100% and
66.6%, respectively. On the other hand, there are neither
signiﬁcant difference (p >0.05) in TB diagnosis between dif-
ferent types of specimens nor between sputum and other
specimen types (Table 4).
Evaluation of used diagnostic methods
TABLE 1. Frequency of tuberculosis (TB) -positive cases with different malignancies during the study period
TB site Malignant condition
1st year
n = 44 (100%)
2nd year
n = 37 (100%)
3rd year
n = 19 (100%)
PTB Bronchogenic 5 (11.3) 11 (29.7) 3 (15.8)
Haematological 4 (9.1) 8 (21.6) 5 (26.3)
Solid tumours 5 (11.3) 4 (10.8) 3 (15.7)
ETB Bronchogenic 2 (4.5) 0 (0) 0 (0)
Haematological 4 (9.1) 2 (5.4) 2 (10.5)
Solid tumours 9 (20.4) 7 (18.9) 2 (10.5)
1. Relation between positive PTB and ETB 2. Relation between PTB and ETB in different malignancy groups 3. Relation between different types of malignancy
v2 = 7.661, p <0.05* v2 = 13.901, p <0.05* v2 = 1.696, p >0.05
*Signiﬁcant.
PTB, pulmonary TB; ETB, extrapulmonary TB.
TABLE 2. Prevalence of PTB and ETB in different patients’
demographic characteristics
TB disease
demographic
characteristics
ETB
n = 28
PTB
n = 48 p-value
Age (mean ± SD) years 42.4 ± 14.2 49.4 ± 18.6 v2 = 0.534; p >0.05
Gender
Female 17 (60.7%) 25 (52.1%) v2 = 0.423; p >0.05
Male 11 (39.3%) 23 (47.9%)
TB risk factors (%)
Diabetes mellitus 0 3 (6.3%) p >0.05
Hypertension 0 3 (6.3%) p >0.05
Smoking 1 (3.6%) 2 (4.2%) p >0.05
Renal disorder 0 2 (4.2%) p >0.05
Hepatosplenic disease 2 (7.1%) 3 (6.3%) p >0.05
Old age > 55 year 7 (25%) 17 (35.4%) p >0.05
Young age <14 year 0 3 (6.3%) p >0.05
Anaemia 1 (3.6%) 4 (8.3% p >0.05
TB history 1 (3.6%) 3 (6.3%) p >0.05
Close contact with TB case 0 1 (2.1%) p >0.05
Congenital CV disorder 1 (3.6%) 0 p >0.05
Occupation 1 (3.6%) 0 p >0.05
TB, tuberculosis; PTB, pulmonary TB; ETB, extrapulmonary TB; CV, cardiovascular.
TABLE 3. Relation between genders and smear-positive
sputum samples in different age groups
Gender Female Male
p-valueZN smear
Positive
(%)
Negative
(%)
Positive
(%)
Negative
(%)
Age groups (years)
0–14 3 (13.6) 0 3 (12) 0 >0.05
15–24 0 0 3 (12) 2 >0.05
25–34 0 0 3 (12) 0 >0.05
35–44 5 (22.8) 2 3 (12) 0 >0.05
45–54 8 (36.3) 2 7 (28) 0 >0.05
55–64 3 (13.7) 0 3 (12) 0 >0.05
>65 3 (13.6) 5 3 (12) 0 <0.05*
Total 22 (100) 9 25 (100) 2 <0.05*
Frequency of
ZN smear
positivity
70.9 92.5
*Signiﬁcant.
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Different diagnostic methods used were evaluated with
regards to diagnostic efﬁciencies and recovery rates. The
highest overall diagnostic efﬁciency of the methods used was
achieved using all three methods LJ, MGIT and in the PTB
group. The highest diagnostic efﬁciency in ETB was in smears
positive using a combination of MGIT and artus real-time
PCR. However, PCR was able to detect TB solely in one case
of smear-positive PTB and three cases of smear-negative ETB.
The overall proportion of the total TB isolates (number of
conﬁrmed positive cultures by MGIT or LJ/total number of
positive cultures by both methods) that were positive by
MGIT was 85% compared with 80.8% for the reference stan-
dard, LJ. Of all culture-positive specimens, 81.7% of smear-
positive and 100% of smear-negative specimens were positive
by MGIT whereas LJ recovery rates were 93.3% and 23% for
smear-positive and smear-negative specimens, respectively.
These data indicate that MGIT liquid medium was signiﬁcantly
more sensitive than the LJ solid culture medium in
smear-negative specimens (p <0.05). In contrast, there was
no statistical difference (i.e. p >0.05) in sensitivity between
the two culture media in smear-positive and total samples
(Table 5).
The overall proportion of total TB isolates (number of
conﬁrmed positive cultures by artus real-time PCR or LJ/
total number of positive cultures by either method) that
were positive by PCR was 98.7%, compared with 77.6% for
LJ. Of all culture-positive specimens, 98.4% of smear-positive
and 100% of smear-negative specimens were positive by PCR
whereas LJ recovery rates were 91.8% and 20% for smear-
positive and smear-negative specimens, respectively. These
data indicate that artus real-time PCR was signiﬁcantly
(p <0.05) more sensitive than the LJ solid culture medium in
smear-negative samples. There was no signiﬁcant difference
in smear-positive and total samples (Table 6).
Comparison between MGIT and artus real-time PCR was
performed using the chi-square method (Table 7). Real-time
PCR showed more signiﬁcant (p <0.05) sensitivity of total
samples than MGIT using LJ as the reference standard. Addi-
tionally, negative predictive value (NPV) of PCR versus LJ
was more signiﬁcant than that for MGIT versus LJ (p <0.05).
TABLE 4. Relation between type of specimens and prevalence of tuberculosis (TB)
Specimen ZN result TB positive (%) TB negative (%)
Total
TB positive
Efﬁciency= (
P2
TB positive/n)
*100 (%)
v2, p-value between
all types at
Sputum n = 58 Smear-positive 32 (55.2) 3 (5.2) 44 75.8 v2 = 6.478, p >0.05
Smear-negative 12 (20.7) 11 (19)
Pus n = 30 Smear-positive 20 (66.7) 3 (10) 23 76.6 v2, p-value between
specimen and sputumSmear-negative 3 (10) 4 (13.3)
Ascetic ﬂuid n = 3 Smear-positive 3 (100) 0 3 100 v2 = 0.032, p >0.05
Smear-negative 0 0
BAL n = 9 Smear-positive 6 (66.7) 2 (22.2) 6 66.6
Smear-negative 32 (55.2) 3 (5.2)
ZN, Zeil–Neelsen;
P2
, algebraic sum; BAL, bronchoalveolar lavage.
TABLE 5. Comparison between recovery rates of LJ and MGIT to all positive cultures
ZN smear MGIT/LJ+ MGIT+/LJ) MGIT)/LJ+ MGIT/LJ)
Total
positive
cultures MGIT+
MGIT
recovery rate (%) LJ+
LJ recovery
rate (%) v2, p
Smear positive n = 69 45 4 11 9 60 49 81.7 56 93.3 0.769, >0.05
Smear negative n = 31 3 10 0 18 13 13 100 3 23 48, <0.05*
Total n = 100 48 14 1 27 73 62 85 59 80.8 0.106, >0.05
*Signiﬁcant; v2, chi-square; PTB, pulmonary tuberculosis; ETB, extra-pulmonary tuberculosis; LJ, Lowenstein–Jensen; MGIT, Mycobacterium growth indicator tube; real-time
PCR, polymerase chain reaction.
TABLE 6. Comparison between recovery rates of positive LJ cultures and artus real-time PCR
ZN smear LJ/PCR+ PCR+/LJ) PCR)/LJ+ LJ/PCR)
Total positive
PCR and LJ PCR+
PCR recovery
rate (%) LJ+
LJ recovery
rate (%) v2, p
Smear-positive n = 69 55 5 1 8 61 60 98.4 56 91.8 0.229, >0.05
Smear-negative n = 31 3 12 0 16 15 15 100 3 20 53, <0.05*
Total n = 100 58 17 1 24 76 75 98.7 59 77.6 2.5, >0.05
*Signiﬁcant; v2, chi-square; PTB, pulmonary tuberculosis; ETB, extra-pulmonary tuberculosis; LJ, Lowenstein–Jensen; real-time PCR, polymerase chain reaction.
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Antituberculosis susceptibility test results
An indirect anti-TB sensitivity (AST) test against rifampin and
isoniazid using MGIT was performed on culture-positive iso-
lates; 69.4% of isolates with respect to total positive culture
isolates were from PTB cases and 30.6% of isolates were
from ETB cases. Of all tested isolates 51% were sensitive to
rifampin and isoniazid, 20.4% were resistant to isoniazid only,
and 28.6% isolates were resistant to both drugs. Our study
detected a signiﬁcant difference (p <0.05) between different
malignancy groups and presence of isolates resistant to
rifampin or isoniazid. The different malignancy groups
included bronchogenic, haematological and solid tumours
other than bronchogenic cancers. The relation between the
AST results in PTB and ETB groups showed that there was
only signiﬁcant resistance (p <0.05) to isoniazid only (Table 8
and Fig. 1).
Discussion and Conclusion
Cancer is the second leading cause of death after coronary
artery disease [19]. Tuberculosis and cancer share similarities
that lead to a serious challenge in their diagnosis [6,20]. The
WHO estimated the burden of TB disease globally in 2008,
2009 and 2010; the average incidence rate of TB in Egypt (all
forms of TB) was estimated at 19 per 100 000. Our study
was carried out during 2007–2010 and the study population
comprised cancer patients (n = 100) who were suspected by
the clinicians of having TB. A total of 76 patients were con-
ﬁrmed by the study protocol to have TB infection. Although
detection of TB was not performed in a wide range of
patients with cancer, it is clear that these patients comprise
a considerable proportion of the estimated TB-positive cases
detected in Egypt by WHO [21].
In the present study, the frequencies of TB-positive cases
in bronchogenic, haematological and solid tumour malignancy
groups were 21%, 25% and 30%, respectively. Therefore,
coexistence of TB with cancer was more common in the
solid tumour malignancy group, followed by the haematologi-
cal malignancy group. This ﬁnding is in agreement with those
of previous studies [20,22,23].
There was no signiﬁcant difference in TB detection among
female and male patients in our study although a higher male
ratio was reported previously [20]. According to the most
recent 16th global report on tuberculosis, published in 2011
by WHO, an excess of male pulmonary TB cases was
detected in all regions of the world including Egypt [21]. It
was suggested that there is sex bias in TB surveys [24]. This
was attributed to the difﬁcult access for female patients to
healthcare units, as well as to the poor quality of sputum
TABLE 8. Antituberculosis susceptibility of Mycobacterium isolates
TB infection site (%) AST result
Associated malignant condition
Total (%)
Bronchogenic (%) Haematological (%) Solid tumours other
than bronchogenic (%)
PTB (69.4) Sensitive 6.1 14.3 10.2 30.6
Resistance to INH and RIF 4.1 4.1 10.2 18.4
Resistance to INH only 16.3 4.1 0 20.4
ETB (30.6) Sensitive 2 8.2 10.2 20.4
Resistance to INH and RIF 0 0 10.2 10.2
Resistance to INH only 0 0 0 0
v2, p-value of AST results between different types of malignancy
Sensitive Resistance to INH and RIF Resistance to INH only
v2 = 2.716; p >0.05 v2 = 7.361; *p <0.05 v2 = 8.095; *p <0.05
v2, p-value of AST results between pulmonary
and extrapulmonary positive TB
v2 = 0.731; p >0.05 v2 = 0.691; p >0.05 v2 = 8.526; *p <0.05
TB, tuberculosis; PTB, pulmonary TB; ETB, extrapulmonary TB; AST, anti-tuberculosis susceptibility test; INH, isoniazid; RIF, rifampin.
v2, p-value of AST results between pulmonary and extra-pulmonary positive TB, *Signiﬁcant.
TABLE 7. Comparison between sensitivity, speciﬁcity and
predictive values of MGIT and PCR using LJ as gold stan-
dard
ZN smear Parameter
Statistical contrasts between
MGIT and artus PCR
Positive n = 69 Sensitivity v2 = 9.33; p <0.05*
Speciﬁcity v2 = 0.16; p >0.05
PPV v2 = 0.001; p >0.05
NPV v2 = 4.92; p <0.05*
Negative n = 31 Sensitivity NA
Speciﬁcity v2 = 0.299; p >0.05
PPV v2 = 0.039; p >0.05
NPV NA
Total samples n = 100 Sensitivity v2 = 9.3; p <0.05*
Speciﬁcity v2 = 0.46; p >0.05
PPV v2 = 0.0001; p >0.05
NPV v2 = 6.08; p <0.05*
*Signiﬁcant; v2, chi-square; LJ, Lowenstein–Jensen; MGIT, mycobacterial growth
indicator tube; artus real-time PCR, polymerase chain reaction; ZN, Ziehl–
Neelsen; PPV, positive predictive value; NPV, negative predictive value; NA, not
applicable.
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samples collected from women in some regions. This was
proven in the current study; where frequencies of ZN
smear-positive female and male sputa were 62.5% and 90.4%,
respectively, which was statistically signiﬁcant. Poor sample
quality would have a negative effect on the laboratory diag-
nosis of TB [25]. Age distribution among TB-positive patients
was also interesting in the present work, the mean age of
TB-positive cases detected was 47 ± 17.6 years
(mean ± SD). The only signiﬁcant difference in TB smear-
positive sputum was observed in the older age group,
>65 years.
The current study recorded a signiﬁcant difference
between PTB and ETB in the different malignancy groups in
the ratios; 9.5:1 in bronchogenic malignancy, 2.1:1 in haema-
tological malignancies and 1:1.5 in the other solid malignant
tumours group. These results are in accordance with previ-
ous reports [20].
The study showed that TB infection is related to the stud-
ied risk factors, which included smoking, poverty and a num-
ber of diseases such as hepatosplenic disorders, anaemia,
diabetes mellitus and hypertension. A similar retrospective
study on TB risk factors was carried out in southern Taiwan
[26–28].
The inﬂammation and diagnostic procedures associated
with TB could promote malignancy. The development of
breast carcinoma was thought to be associated with the mul-
tiple chest X-rays needed for the follow-up of a previous TB
infection [29]. Similarly in the present work, one case of
breast cancer had a history of TB, had developed recurrent
TB infection and been subjected to repeated diagnosis. In
addition, three cases with bladder cancer had reported
recurrent TB infections; two had PTB and one had ETB. The
relationship between TB disease and bladder cancer was pre-
viously evaluated [30,31], although the relevant mechanisms
are still unknown.
Two laboratory diagnostic methods were evaluated against
the reference standard LJ medium—artus tuberculosis real-
time PCR and manual MGIT liquid culture medium. The diag-
nostic efﬁciency of each laboratory method was calculated
for all patients. The highest overall diagnostic efﬁciency of
the methods was achieved using all of three methods: LJ,
MGIT and real-time PCR. The highest diagnostic efﬁciency in
ETB was in smear-positive patients using a combination of
MGIT and real-time PCR. However, real-time PCR was able
to detect TB in only one case of smear-positive PTB and
three cases of smear-negative ETB. Similarly, the usefulness
of the Rotor Gene (artus M. tuberculosis RG) PCR assay
was previously described [32].
Rapid and accurate diagnosis of ETB is necessary, although
it has a greater impact on patient management than on limit-
ing the spread of infection [33]. This is not often an easy
task, because symptoms vary according to the infected
organs and patients may have few or even no classic signs
and symptoms. The recovery rates of artus real-time PCR,
MGIT and LJ were compared in our study. MGIT was signiﬁ-
cantly more sensitive than LJ in recovering M. tuberculosis
from smear-negative specimens, which was also concluded
by other studies [34,35]. Comparison between the recovery
rates of artus real-time PCR and LJ showed higher recov-
ery (98.7%) for PCR than for LJ (77.6%).
Sensitivity and speciﬁcity of artus real-time PCR were
estimated as 96.55% and 59%, respectively. In another study,
the sensitivity and speciﬁcity of the ABI prism artus
M. tuberculosis assay using culture as a standard were
reported as 97.8% and 85.1%, respectively [15]. Considering
LJ as the reference standard in the present study, artus
real-time PCR had signiﬁcantly higher sensitivity in both the
smear-positive and the total samples groups than the MGIT
results. Agreement between LJ and PCR was previously
reviewed [36].
Comparison of the cost of the laboratory diagnosis
revealed that the artus real-time PCR method using artus
TM tuberculosis had the highest ﬁnancial cost. However,
time elapsed to get the result was considerably the lowest.
Regarding the cost of infection spread as the resutl of a
delay in TB diagnosis, artus real-time PCR is considered the
most cost-effective method.
The AST were performed on culture-positive TB isolates.
The MGIT system has been thoroughly evaluated for AST of
M. tuberculosis towards anti-tuberculosis drugs and a good
concordance with the reference standard proportion method
was reported [37–39]. In the present study, the bacillary
loads in specimens were low as indicated by ZN smears, so
an indirect test was performed. The test was carried out for
two of the most important ﬁrst-line drugs; rifampin and iso-
niazid. Indirect AST using MGIT was previously reported to
have excellent agreement with the proportion method [39].
0.00%
5.00%
10.00%
15.00%
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FIG. 1. Anti-tuberculosis susceptibility test (AST) in cases with dif-
ferent malignant conditions. MDR-TB, multidrug-resistant tuberculo-
sis; INH, isoniazid.
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In the present work, bronchogenic malignancies’ patients
had the highest rate of isoniazid-resistant TB isolates. On the
other hand, there was a signiﬁcantly larger percentage of
multidrug-resistant TB (MDR-TB) isolates (resistant to both
isoniazid and rifampin) among patients with solid tumours
other than the bronchogenic group.
Consequently, the TB resistance pattern is not homoge-
neous among isolates from different malignancy groups.
However, we reported a signiﬁcantly higher prevalence of
MDR-TB isolates in PTB than in ETB with ratios of 18.4%
and 10.2%, respectively. Differences in drug-resistance pro-
ﬁles of M. tuberculosis isolates causing PTB and ETB were
previously reported [40], so an investigation for drug resis-
tance in immunocompromised patients, such as those with
cancer, is recommended before starting anti-TB therapy
[41].
MDR-TB isolates were detected in all patients with a his-
tory of TB. This can be attributed to inadequate case man-
agement, patient non-compliance with treatment, or
inadequate drug regimens [42–44]. Therefore, drug resis-
tance should be suspected in patients with anti-TB treatment
history or treatment failure. It was of particular importance
to note in this study the signiﬁcant number of new TB cases
with MDR-TB isolates. Recently, an exponential increase in
the rate of MDR-TB among new cases has been reported.
Global trends in rates of MDR-TB are unclear among new
cases and need continuous surveillance [21,45].
Interestingly, no TB isolate in the present study was resis-
tant to rifampin only. These results were previously reported
[46], where mono-resistance to rifampin was rarely detected
and nearly all rifampin-resistant isolates were MDR-TB. This
result highly recommends the use of rifampin resistance as a
reliable marker for MDR-TB in the population.
Overall, drug resistance could be observed much earlier
by the MGIT method (mean, 5 days) than by the proportion
method (mean, 16 days). Other studies reported rapid
detection of isoniazid-resistant and rifampin-resistant
M. tuberculosis strains using the MGIT susceptibility system
[46–48].
Widespread use and misuse of ﬁrst-line and second-line
anti-TB drugs has led to acquired resistance [43]. Conse-
quently, MDR-TB isolates have developed that increase TB’s
worldwide morbidity and mortality.
Our study concluded that specimen quality is the key in
accurate diagnosis of TB, so education of patients about the
proper sputum collection procedure is important for opti-
mum specimen quality. Anti-tubercular susceptibility is essen-
tial for proper TB treatment. Indirect anti-tubercular
susceptibility testing using MGIT is an easy, fast and helpful
tool to test the susceptibility of TB isolates. MGIT-rifampin
resistance may be used as a reliable surrogate marker for
detection of MDR-TB. Inclusion of MGIT liquid culture in
routine laboratory work is recommended. A real-time PCR
method using artus TM tuberculosis, was the most cost-
effective method for TB diagnosis and is recommended
before starting anticancer therapy. Repeated national surveil-
lance on immunocompromised patients should be strength-
ened so as to stop the spread of MDR-TB.
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